The global API CDMO Services market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.
Factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for the development of pharmaceutical manufacturing segments, and rise in R&D activities for drugs contribute to this growth.
However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
- Comprehensive analysis of the global API CDMO Services landscape
- Highlights key trends related to product segmentation, company formation, revenue, and market share
- Latest development and M&A activity
- Evaluation of key market trends, drivers, and affecting factors
- Market size to highlight emerging pockets of opportunity
Segmentation by Type:
- Traditional API CDMO
- Highly Potent API CDMO
Segmentation by Application:
- Pharmaceutical Company
- Research Institute
Market by Region:
- Americas
- APAC
- Europe
- Middle East & Africa
Company's Coverage:
- EUROAPI
- Cambrex
- Recipharm
- Thermo Fisher Scientific
- CordenPharma
- Samsung Biologics
- Lonza
- Catalent
- Siegfried
- PiramalPharma Solutions
- Boehringer-Ingelheim
- Wuxi Apptec
- Pharmaron Beijing
- Asymchem Laboratories (Tianjin)
- Porton
- SEQENS
- Lebsa
- Langhua Pharma
Key Questions Addressed in this Report:
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market